Similarly, compared to Bevacizumab group, the percentage of CD44+ cells decreased significantly in MDA-MB-231/MDA-MB-468 tumor tissues of Bevacizumab + SHH002-hu1 group (MDA-MB-231: **p < 0.01, MDA-MB-468: **p < 0.01) (Supplementary Fig. 6B, C). This evidence concerns the gene CD44 and neoplasm.